What Is a Clinical Trial? FDA Phases for Investors

Educational beginner investing fda biotech clinical-trials

Clinical Trial Phases Compared

The fastest way to read a clinical-trial headline is to ask what phase the study is in and what question that phase is built to answer. FDA's clinical research guide lists typical participant ranges, study lengths, and purposes for Phase 1 through Phase 4 drug studies. FDA, Step 3: Clinical Research.

What Is a Clinical Trial?

A clinical trial is a planned research study involving human volunteers. In drug development, trials usually follow earlier laboratory and animal research and are run under a protocol that defines the study question, participants, treatment plan, assessments, timing, and analysis approach.

FDA says clinical research refers to studies or trials done in people. The agency also explains that developers consider what they want to accomplish in each clinical research phase before beginning the Investigational New Drug process, commonly called the IND process. FDA, Step 3: Clinical Research.

This guide focuses mainly on drugs and biologics. Medical devices can involve clinical studies too, but FDA device pathways use different terms, including 510(k), De Novo, Premarket Approval, and Investigational Device Exemption. FDA, Device Approvals and Clearances.

For a public-company reader, the useful question is not "is this good or bad?" The useful question is narrower: what stage is the program in, what did the trial actually test, and what step comes next?

Before Human Studies: Preclinical Research and IND

Before most investigational drugs are tested in people, developers study them in laboratory and animal models. FDA describes preclinical research as work that answers basic questions about safety before human testing begins. FDA, Step 2: Preclinical Research.

For most investigational drugs and biologic products, the sponsor submits an IND application before beginning clinical research. FDA says an original IND review period is 30 days from receipt. The applicant may proceed after FDA notification or after 30 days if the IND is not placed on clinical hold. FDA, IND Applications Overview.

A clinical hold is not a vague delay. FDA defines it as an order to delay a proposed clinical investigation or suspend an ongoing one. When an ongoing study is placed on hold, FDA says no new subjects may be recruited and given the investigational drug. FDA, Clinical Hold Procedures.

Phase 1: Safety and Dosage

Phase 1 is usually the first stage of human testing. FDA describes Phase 1 studies as closely monitored trials that gather information about how a drug interacts with the human body, including dosage and acute side effects. FDA lists a typical Phase 1 range of 20 to 100 healthy volunteers or people with the disease or condition. FDA, Step 3: Clinical Research.

The central question is usually safety and dose selection. Researchers may look at how the body absorbs, distributes, metabolizes, and clears a drug. They may also test dose escalation, where different groups receive higher doses under close monitoring.

Oncology is a common exception to the "healthy volunteer" mental model. FDA notes that when a new drug is intended for cancer patients, Phase 1 studies are conducted in patients with that type of cancer. That matters because early oncology trials may report response signals, but the trial can still be mainly designed around safety and dose finding.

Phase 2: Efficacy and Side Effects

Phase 2 studies usually involve people with the disease or condition being studied. FDA describes Phase 2 as focused on efficacy and side effects, typically involving up to several hundred people and lasting several months to two years. FDA also notes that these studies usually are not large enough by themselves to show whether a drug will be beneficial. FDA, Step 3: Clinical Research.

This is where readers often see "proof of concept" language. In plain English, that usually means the sponsor is looking for enough evidence to justify a larger and more expensive trial. It does not mean the evidence is final.

Phase 2 results can be messy. A study may hit a biomarker endpoint but miss a symptom endpoint. One dose may look better than another. Safety events may change the risk discussion. The next step may be a Phase 2b study, a redesigned Phase 3 trial, a regulatory meeting, or no immediate advance.

Phase 3: Larger Evidence Before FDA Review

Phase 3 studies are usually larger, longer, and more consequential. FDA says Phase 3 studies are designed to demonstrate whether a product offers a treatment benefit to a specific population. FDA lists a typical Phase 3 range of 300 to 3,000 volunteers with the disease or condition. FDA, Step 3: Clinical Research.

These studies often provide much of the safety information used in regulatory review. Because Phase 3 trials include more people and last longer than earlier trials, they are more likely to detect longer-term or less common adverse reactions.

If the data support submission, the sponsor may file a marketing application. For many drugs, that is a New Drug Application. For biologic products, it is often a Biologics License Application. FDA review is a separate step where the agency examines submitted data and decides whether to approve the product. FDA, Step 4: FDA Drug Review.

Phase 4: Post-Market Monitoring

Phase 4 studies happen after FDA approval. FDA describes Phase 4 trials as studies carried out once the drug or device has been approved during post-market monitoring. FDA, Step 3: Clinical Research.

Post-market studies can examine longer-term safety, broader use, additional patient groups, real-world treatment patterns, or required follow-up after certain approval pathways.

For biotech and pharmaceutical news, Phase 4 updates can still matter as context. They can affect labels, warnings, physician confidence, post-approval obligations, and future development plans. They are different from pre-approval trials because the product already has at least one approved use.

Endpoints and Trial Design Terms

The phase tells you where the study sits. The endpoint tells you what the study is trying to measure. ClinicalTrials.gov defines an outcome measure as a planned measurement used to determine the effect of an intervention, and it defines the primary outcome measure as the most important planned outcome in the protocol. ClinicalTrials.gov Glossary.

Design terms matter too. A randomized trial assigns participants to groups by chance. Blinding limits who knows which treatment a participant receives. A comparator can be placebo, standard of care, or another active treatment. An open-label study, where participants and researchers know the assigned treatment, can still be useful, but some outcomes require extra care when interpreting results.

Interim analyses and data cutoffs are another source of confusion. An interim result is not always the final trial result. A data cutoff tells readers how much follow-up had happened when the analysis was performed. In some diseases, longer follow-up can change the interpretation of both benefit and safety.

A statistically significant result and a clinically meaningful result are related but separate ideas. Statistical significance depends on the trial's analysis rules. Clinical meaning depends on whether the size and type of benefit matter for patients, regulators, and medical practice.

FDA Terms That Are Not Approval

FDA-related headlines often use words that sound more final than they are. Many describe a pathway, meeting, designation, or review status. They can be important, but they are not automatically approvals.

PDUFA stands for Prescription Drug User Fee Act. FDA's Priority Review page explains that PDUFA created a two-tier review goal structure: 6 months for Priority Review and 10 months for standard review. FDA also has an industry FAQ on applications subject to PDUFA target dates. A target date can be a major calendar item in biotech news, but it is still a review goal, not an outcome. FDA, PDUFA Target Dates FAQ.

How to Decode a Clinical-Trial Headline

A trial headline often compresses months or years of work into one sentence. A neutral reading starts by separating the event, the evidence, and the next step.

Where Clinical-Trial Updates Appear on StockTitan

StockTitan organizes clinical-trial and FDA updates so readers can connect a headline with related filings, company disclosures, and regulatory context.

Frequently Asked Questions

Sources and Methodology

The information provided in this article is for educational and informational purposes only. It does not constitute financial advice, investment recommendation, or an endorsement of any particular investment strategy. Past performance does not guarantee future results. Investors should conduct their own research and consult with a qualified financial advisor before making investment decisions.